Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises.

INTRODUCTION: Triple-negative breast cancer (TNBC) presents unique challenges indiagnosis and treatment.Resveratrolexhibits potential as a therapeutic intervention for TNBC byregulating various pathways such as the PI3K/AKT, RAS/RAF/ERK, PKCδ,and AMPK, leading to apoptosis through ROS-mediated CHOP activationand the expression of DR4 and DR5. However, the clinical efficacy of resveratrol is limited due to itspoor biopharmaceutical characteristics and low bioavailability at thetumor site. Nanotechnology offers a promising approach to improvingthe biopharmaceutical characteristics of resveratrol to achieveclinical efficacy in different cancers.

AREASCOVERED: Thismanuscript provides a comprehensive discussion on thestructure-activity relationship (SAR), underlying anticancermechanism, evidence of activity in in-vitro/in-vivo investigations,and the significance of nanotechnology-mediated delivery ofresveratrol in TNBC.

EXPERTOPINION: Advanced nano-formulations of resveratrol such as oxidized mesoporouscarbon nanoparticles, macrophage-derived vesicular system,functionalized gold nanoparticles, etc. have increased theaccumulation of loaded therapeutics at the tumor-site, and avoidoff-target drug release. In conclusion, nano-resveratrol as astrategy may provide improved tumor-specific image-guided treatmentoptions for TNBC utilizing theranostic approach.